A detailed history of Kynam Capital Management, LP transactions in Liquidia Corp stock. As of the latest transaction made, Kynam Capital Management, LP holds 2,266,328 shares of LQDA stock, worth $25.6 Million. This represents 1.86% of its overall portfolio holdings.

Number of Shares
2,266,328
Previous 916,574 147.26%
Holding current value
$25.6 Million
Previous $11 Million 106.06%
% of portfolio
1.86%
Previous 0.86%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.9 - $14.11 $12 Million - $19 Million
1,349,754 Added 147.26%
2,266,328 $22.7 Million
Q2 2024

Aug 14, 2024

SELL
$11.96 - $15.71 $15.9 Million - $20.9 Million
-1,331,750 Reduced 59.23%
916,574 $11 Million
Q1 2024

May 15, 2024

SELL
$11.35 - $16.73 $5.11 Million - $7.53 Million
-450,000 Reduced 16.68%
2,248,324 $33.2 Million
Q4 2023

Feb 14, 2024

BUY
$5.77 - $12.19 $4.03 Million - $8.51 Million
698,324 Added 34.92%
2,698,324 $32.5 Million
Q3 2023

Nov 14, 2023

BUY
$6.27 - $8.15 $2.24 Million - $2.92 Million
357,756 Added 21.78%
2,000,000 $12.7 Million
Q1 2023

May 15, 2023

SELL
$5.72 - $7.91 $632,614 - $874,822
-110,597 Reduced 6.31%
1,642,244 $11.3 Million
Q4 2022

Feb 14, 2023

BUY
$4.68 - $6.54 $282,854 - $395,271
60,439 Added 3.57%
1,752,841 $11.2 Million
Q3 2022

Nov 14, 2022

BUY
$3.73 - $8.39 $714,981 - $1.61 Million
191,684 Added 12.77%
1,692,402 $9.21 Million
Q2 2022

Aug 15, 2022

BUY
$3.37 - $7.55 $1.15 Million - $2.57 Million
341,044 Added 29.41%
1,500,718 $6.54 Million
Q1 2022

May 13, 2022

SELL
$5.14 - $7.38 $1.06 Million - $1.53 Million
-207,162 Reduced 15.16%
1,159,674 $8.33 Million
Q4 2021

Feb 14, 2022

BUY
$2.71 - $5.17 $3.7 Million - $7.07 Million
1,366,836 New
1,366,836 $6.66 Million

Others Institutions Holding LQDA

About Liquidia Corp


  • Ticker LQDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 64,362,300
  • Market Cap $728M
  • Description
  • Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil inje...
More about LQDA
Track This Portfolio

Track Kynam Capital Management, LP Portfolio

Follow Kynam Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kynam Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Kynam Capital Management, LP with notifications on news.